
How a Chromosome Translocation Affects Gametogenesis in Human Male and Female? A Clinical Study Approach

Salma Kaddouri-Kaddouri^a, Cintia Concepción-Lorenzo^b,
Rubí Rodríguez-Díaz^{a,b}, Stephany Hess-Medler^a, Jonay González-Pérez^b,
Rebeca Vaca-Sánchez^b, Delia R. Báez-Quintana^{a,b}
and Raquel Blanes-Zamora^{a,b*}

DOI: 10.9734/bpi/rdmmr/v13/2710F

ABSTRACT

Purpose: To study if females with balanced translocation (BT) have a normal ovarian response compared to normal karyotype XX women. And in male with BT, to determine if spermiogram is affected compared to normal XY karyotype men.

Methods: A retrospective analysis in a public IVF centre of 3249 karyotyped patients between 2008 and 2016, 2276 women, and 973 men. Cycle parameters, oocytes and embryo outcomes were examined. Spermiogram of 19 males with BT were compared with 93 normal XY patients. And 12 women with BT were compared with 93 control normal karyotype XX group (CN). An equivalent control group (EQc) of 12 patients was also selected to be accurate with the BT statistical contrast with normal karyotype in both members of the couple. Results of all cycles were compared.

Results: 19 males (1.9%) and 12 women (0.5%) had BT. Men with BT were older than CN group (37.86 ± 5.62 vs. 40.26 ± 4.18; t57,590 = -3,169, $p = 0.02$). Motility (A+B) in fresh was not different (44.8 ± 17.96 vs. 42.28 ± 16.60 in control vs. pathologic; $p=0.423$) but had a significant lower concentration of spermatozoa (37.69 ± 37.36 vs. 23.49 ± 22.75 mill/ml; t65,04 = 3,191, $p = 0.002$). After capacitation, progressive motility (A + B) MSR (motile spermatozoa recovery) (70.86 ± 20.57 vs. 80.25 ± 18.94 control vs. pathologic; t292 = -2,589, $p = 0.010$). Women BT were older than CN (36.55 ± 4.06 vs. 33.96 ± 3.70; $p < 0.001$), FSH was not different (6.54 ± 1.30 vs. 6.39 ± 1.72; $p = 0.618$). BMI (body mass index) was higher in BT (26.73 ± 5.36 vs. 24.32 ± 3.98; $p = 0.011$). Mature MII oocytes obtained was slightly higher in BT with no statistical difference (11.28 ± 4.51 vs. 9.68 ± 6.13; $p = 0.135$), similar maturation rate (90.38% vs. 89.20%; $p = 0.602$) and higher number of divided embryos with no statistical difference (9.03 ± 3.53 vs. 7.28 ± 5.25; $p = 0.09$). Comparison with EQc to avoid differences with age, BMI and FSH values, showed no statistical differences in any of the studied parameters.

Conclusions: Men with a BT have poorer factors affecting sperm quality than control normal XY males. It is recommended to provide a karyotype in males with pathologic spermiogram prior to reproductive treatment. Women carriers of a BT do not have a diminished response pattern to COS (controlled ovarian stimulation) than CN of infertile women with normal karyotype XX. In both cases, an ICSI cycle with PGT and adequate genetic counseling are highly recommended.

Keywords: Translocations; robertsonian; reciprocal; gametogenesis; fertility; ovarian response.

1. INTRODUCTION

The incidence of balanced chromosomal rearrangements in the general population is 1/500 individuals (0.2%), but in infertile patients this percentage is higher than in general population.

^a Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.

^b Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

*Corresponding author: E-mail: rblaneszamora@yahoo.es;

Chromosomal aberrations are involved in reproductive failures, chromosomal translocations, abnormal gametogenesis, implantation failure and recurrent pregnancy loss. Chromosomal translocations are rearrangements involving the exchange of segments between chromosomes and a significant proportion of rearrangements include additional complexity that is not visible by conventional karyotype analysis.

There are two types of translocations: Reciprocal and Robertsonian translocations. Balanced translocations are typically benign, but meiosis in germ cells with balanced translocations may result in meiotic arrest and subsequent infertility, or in unbalanced gametes, with attendant risks of miscarriage and unbalanced progeny.

Reciprocal translocations (RT) are the most common chromosomal rearrangements in humans, with a prevalence of 1 every 500-625 born in the general population [1]. Reciprocal translocation is produced when two non-homologous chromosomes exchange segments and, if no genetic material is gained or lost and no truncation of a gene occurs, patients can be phenotypically normal, but they will have a higher risk of recurrent pregnancy loss. In the Robertsonian translocation (ROT) two acrocentric chromosomes as 13, 14, 15, 21 and 22 fuse at the centromere [2], ROT have low impact on cell function, but when meiosis happens can produce nullisomic or disomic gametes and if fertilization takes place, originates monosomic or trisomic zygotes. The imbalance can be caused by the duplication of a chromosome segment and the other chromosome deleted. In addition, translocation carriers may have an increased risk of having descendants with physical or mental anomalies [3]. The great genetic imbalances produced by unbalanced combinations are responsible for early pregnancy loss or even for implantation failure and if the imbalances are moderate, can conduce to recognizable miscarriage or stillbirth. Those translocations can be originated by a reciprocal exchange between two non-homologous chromosomes [4], being inherited from one of the progenitors or produced *de novo* [5]. Robertsonian translocations can be formed *de novo* (can occur in 50% of cases) or inherited from a progenitor [6,7]. The prevalence of ROT in the general population is 1.2 every 1000 people, 1.8% in couples with recurrent abortions and 2-3% of infertile men [8,9]. When this junction occurs, extremes are lost and the two chromosomes are linked giving rise to a metacentric or submetacentric chromosome [10].

Translocations will affect or not depending on the pattern of segregation in meiosis. Whether the translocation is Robertsonian or reciprocal, the only mode of segregation that will provide normal balanced gametes is alternate segregation. A study published by Zhang et al. [11] showed that the proportion of alternate segregation was lower in female than in male carriers. Although the sex of the translocation carrier does affect the segregation pattern, it does not affect the stability of non translocated chromosomes during meiosis [12].

It is known that men with ROT, even if they are phenotypically normal, present fertility problems producing an increase in the number of spermatozoa with unbalanced genetic loading ranging between 3.4% and 40% and resulting in infertility, oligozoospermia, azoospermia, oligoastenoospermia, recurrent pregnancy loss and offspring chromosomally unbalanced [13,14,15]. On the other hand, men carriers of balanced RT present an unbalanced sperm frequency between 18.6% and 80.7% [16]. Ultimately, it is well known that infertile men with non-obstructive semen pathologies have a higher frequency of chromosomal abnormalities compared to fertile men with normal semen [17].

Besides that, we must also consider the inter-chromosomal effect (ICE) that will increase the rate of aneuploidies in gametes [18]. Only those conceptuses with minor imbalances may result in the birth of a normal child or a normal carrier.

The objective of this study is to assess possible repercussions and effects in the seminal quality when the male is the carrier of a chromosomal translocation compared to a control group of infertile patients but with normal karyotype 46 XY. In addition, to determine the relationship among female translocation carriers and controlled ovarian stimulation (COS) as well as oocytes quality, fertilization rate and embryo development at the University Hospital Complex of Canary Islands Hospital

Universitario de Canarias (CHUC), to give appropriate counselling to patients affected with a chromosomal translocation.

The main objective is to lay the foundations for the implementation of a treatment plan in a Human Reproduction unit when it comes to couples in which the male has a pathological spermiogram or a chromosomal translocation is diagnosed and when the female is the diagnosed carrier with chromosomal translocation.

It is of major importance to proceed with those patients to have an IVF treatment and a preimplantation genetic testing (PGT) to select only normal euploid embryos to transfer. That strategy significantly reduces pregnancy losses and increase the number of viable pregnancies, being a safer method for conceiving a live birth child, at least for translocation carriers with recurrent pregnancy loss and no previous live births [19].

Furthermore, there are studies [19,20] suggesting that women carriers of a translocation may have an increased risk for poor response to COS and that it could be decisive to obtain enough embryos to select the healthy ones, before transferring to the uterus. We want to determine if the response to oocyte stimulation is lower than that of a control XX women or if it does not affect the ovarian response.

In addition, when the carrier of a chromosomal translocation is the male partner, we want to assess how it affects sperm quality and guide them to perform an Intracytoplasmic sperm injection (ICSI) with PGT.

2. MATERIALS AND METHODS

2.1 Patients Groups

2.1.1 Female study

A retrospective study was performed in 3249 karyotyped patients, 2276 female and 973 males, attending at the Reproductive Unit of CHUC, between January 2008 and December 2016. We analysed only reciprocal and Robertsonian translocations and a selected random group of 93 patients with normal karyotype for both members of the couple as a control, being excluded couples with no karyotype determination and other pathologies out of this study. A total of 12 female were diagnosed as chromosomal translocation carriers.

We compared age, body mass index (BMI) and female serum follicle stimulant hormone (FSH) on third day of cycle, number of oocytes obtained after COS, rate of mature oocytes (MII), fertilization rate and number of embryos obtained. A second control group was selected, that we denominated "equivalent control" (EQc) with 12 patients matching one by one with the female pathological patients in three items: age, BMI and FSH (Fig. 1).

Approval from the Ethical Committee of our institution was obtained for this study, and permission was achieved as all the research was performed according to the actual guidelines and regulations.

2.1.2 Male study

A total of 19 males were diagnosed as carriers of translocations, both reciprocal and Robertsonian (pathological group) and it was randomly chosen as control group a total of 93 patients with 46 XY normal karyotype. The cycles in which we do not know the karyotype of any of the members of the couple and those cases in which had other alterations than translocation, were excluded from the control group (Fig. 1).

The variables collected were: male age, spermiogram diagnosis and seminal features (volume in fresh, fresh concentration, progressive sperm motility (A + B) in fresh, motile sperm recovery (MSR)

and spermatic progressive motility (A + B). For the diagnosis of the seminogram, the samples were evaluated following recommendations and standards of the World Health Organization [21] where the standards are classified as: Normozoospermia: Concentration ≥ 15 million / ml and $\geq 32\%$ of progressive motile spermatozoa or also more than 39 million total concentration and 40% progressive motiles. Oligozoospermia: Concentration <15 million / ml. Astenozoospermia: progressive motile $<32\%$. Oligoastenozoospermia: concentration <15 million / ml and $<32\%$ progressive motiles. Severe oligozoospermia: concentration <5 million / ml. Cryptozoospermia: Absence of sperm in the sample in fresh, but after centrifugation recovery of few spermatozoa. Azoospermia: There is a total absence of spermatozoa both from the sample in fresh and in the pellet after centrifugation.




Fig. 1. Patient groups

2.2 Controlled Ovarian Stimulation

Antagonist protocol used gonadotrophin stimulation starting from day 2 with the administration of a variable dose of 225-300 mg of rFSH (Puregon®, Organon, France or Gonal-F®, Merck Serono, France) associated or not with urinary gonadotrophin (Menopur®). Antagonist is added subcutaneously diary starting when the leading follicle achieved 14 mm of diameter, 0.1 mg of ganirelix or cetrorelix (Ganirelix, Orgalutran®, Organon, France; Cetrorelix, Cetrotide®, Serono, France). Additionally, Ovitrelle® 250 micrograms of solution for injection in pre-filled pen (Coriogonadotrophin alpha, Merck Serono, Bari, Italy) was administered when follicles had at least 17 mm. Egg retrieval was performed 36 hours after hCG administration.

2.3 Cytogenetic Studies

Cytogenetic preparations were obtained from phytohaemaglutinin (PHA)-stimulated peripheral blood lymphocytes as described by Rooney and Czepulkowski [22]. Chromosome analysis was carried out on G-banded metaphases.

2.4 Embryo Quality

The embryo quality of the obtained embryos was determined following the parameters marked by ASEBIR (Association for the Study of the Biology of Reproduction) [23].

2.5 Statistical Analysis

A frequency analysis of translocations was carried out. Therefore, data were compared with analysis of media differences for independent samples for numerical data, and a chi-square was applied for categorical factors. Also, ANCOVA test was used to neutralize a variable effect. For comparison of gonadotrophin doses administered, a comparison of media was applied. Statistical analysis was

performed using the SPSS vs.21 statistic package and p value <0.05 was considered statistically significant.

3. RESULTS

3.1 Males

When analyzing the age of the men, we obtained for the control group and pathological group 37.86 ± 5.62 and 40.26 ± 4.18 years old respectively ($t_{57,590} = -3,169$, $p = 0.02$), therefore that age was significantly higher for the group of pathological males. In our infertile population, out of a total of 3249 karyotypes analyzed, 973 corresponded to males, and 19/973 (1.9%) of males presented a reciprocal or Robertsonian translocation. 11/19 (57.9%) men were carriers of reciprocal translocations and 8/19 (42.1 %) were carriers of Robertsonian translocations (Table 1).

Table 1. Male translocation diagnosed

Male Translocation
46XY, t(7;9)
45XY, rob(13;14)
45,XY,rob(13;14)(q10;q10)
45,XY,rob(13;14)(q10;q10)
45,XY,rob(13;14)(q10;q10)
45,XY,rob(13;14)(q10;q10)
45,XY,rob(13;14)(q10;q10)
46,XY,t(14;21)(q12;q21)
46,XY,t(1;16)(q22;p13.2)
46,XY,t(3;8)(p21;p23)
46,XY,t(1;9)(q12;q12)
46,XY,der(21)t(Y;21)(q12;p11.1)
46,XY,t(X;6)(p22.3;p21.2)
46,XY,t(1;6)(q32;p23)
46,XY,t(5;11)(p10;p10)
46,XY,t(7;9)(p14;q34)
46,XY,t(4;12)(q28;q23)
46,XY,t(4,7)(p15;p15)
45,XY,rob(15;22)(q10;q10)

When comparing the parameters of the spermiogram of cycles from the two groups studied, we observe that in the group of 46 XY normal men there are 63.2% of normozoospermia (N), 10.9% of oligozoospermia (O), 6.8% of astenozoospermia (As), 13.5% of oligoastenozoospermia (OA), 2.3% of azoospermia (Az), 0.4% severe oligozoospermia (Os) and 3.0% of cryptozoospermia (Cr). Meanwhile in men carrying some translocation, we found 40.4% of normozoospermia, 12.8% oligozoospermia, 6.4% oligoastenozoospermia, 0.0% of severe oligozoospermia, 0.0% cryptozoospermia and 40.4% of azoospermia. There is a significant difference between both groups ($\chi^2_{21} = 8,582$; $p = 0.003$) when the male has a translocation (Fig. 2).

Examining the seminal values, we found significant differences in the seminal volume between the groups ($t_{292} = -6,152$, $p = 0.000$) with average in the control group ($M = 2.95 \pm 1.51$ ml) and in the pathological group of ($M = 4.64 \pm 1.67$ ml). Patients with translocations present greater seminal volume. We also found significant differences between the control and the pathological group in the fresh concentration ($t_{65,04} = 3,191$, $p = 0.002$) with an average of ($m = 37.69 \pm 37.36$ mill/cc) and ($m = 23.49 \pm 22.75$ mill/cc) respectively. The concentration per milliliter in fresh is lower in pathological patients (Table 2).




Fig. 2. Spermogram diagnosis of pathologic vs. control group

Table 2. Spermogram of pathologic group, (36 cycles from 19 patients) vs. control group (258 cycles from 93 patients)

SPERMIOGRAM	Group 0=Control 1=Pathologic	N	Media	SD
Volume (cc)	0	258	2.95	1.51
	1	36	4.63	1.67
Concentration In fresh (mil/cc)	0	258	37.69	37.36
	1	36	23.49	22.75
Mot (a+b) fresh	0	258	44.52	17.96
	1	36	42.26	16.60
Conc.REM (mill/cc)	0	258	30.35	30.22
	1	36	28.61	20.69
Mot. REM (a+b)	0	258	70.86	20.57
	1	36	80.25	18.94

We did not find significant differences in motility (A + B) in fresh ($t_{292} = 0.803$, $p = 0.423$) with a mean in the control group of ($M = 44.8 \pm 17.96$ %) and in the pathological group ($M = 42.28 \pm 16.60$ %). We obtained significance after capacitation in motility (A + B) MSR ($t_{292} = -2,589$, $p = 0.010$) with a mean in the control group of ($M = 70.86 \pm 20.57$ %) and in the pathological group ($M = 80.25 \pm 18.94$ %). We also did not find significant differences in the concentration in MSR ($t_{292} = 0.314$; $p = 0.754$) with one average in the control group of ($M = 30.35 \pm 30.22$ mill/cc) and in the pathological group of ($M = 28,67 \pm 28.69$ mill/cc), being slightly lower in the pathological group.

3.2 Female

Female with pathological karyotypes had a mean age of (36.55 years; TD = 4.06 years), while the control group was (33.96 years; TD = 3.70 years) ($t_{307} = -3.990$; $p < 0.001$), a significant difference was obtained in the age between control and pathological groups. Female age of pathological group was statistically higher than control group. The mean BMI in pathological female was (26.73 kg/m²; TD = 5.36 kg/m²), compared to the control group (24.32 kg/m²; TD = 3.98 kg/m²) ($t_{307} = 3.333$; $p = 0.011$) showed a significant difference, greater in pathological patients.

The pathological group had a significantly higher BMI value than the control group ($p = 0.011$). The mean serum FSH concentration in pathological females was (6.54 mIU/ml; TD=1.30 mUI/ml; Cv = 19.88%) compared with those in the control group (6.39 mIU/ml; TD=1.72 mUI/ml; Cv = 26.92%) ($t_{-0.499} = -3.169$; $p = 0.618$). FSH did not show any significant differences between both groups (Table 3).

Table 3. Comparison of age, BMI and FSH between pathological and control group

P vs C	Age (years)	BMI (Kg/m2)	FSH (mIU/ml)
Control (N=93)	33.96±3.70	24.32±3.98	6.39±1.72
Pathologic (N=12)	36.55±4.08	26.73±5.36	6.54±1.30
<i>p</i>	0.001	0.011	0.618

The Control Equivalent group (EQc) was selected to avoid any difference on those parameters and the results are showed in Table 4.

Table 4. Comparison of age, BMI and FSH between pathological and control equivalent group

P vs EQc	Age (years)	BMI (Kg/m2)	FSH (mIU/ml)
Control EQc (N=12)	33.83±5.18	26.58±4.28	6.18±1.85
Pathologic (N=12)	35.17±5.20	26.88±5.43	6.33±1.50
<i>p</i>	0.536 (NS)	0.883 (NS)	0.825 (NS)

In our infertile population, out of a total of 3249 karyotypes we found that 12/2276 women (0.5%) were carriers of a chromosomal translocation. Translocations detected included 10/12 reciprocal translocations (83.33%) and 2/12 (16.67%) Robertsonian translocations (Table 5).

Table 5. Description of female chromosomal translocations

Translocation in females (N=12)
45, XX, rob(13;14)
45, XX, rob(13;14) (q11;q11)
46, XX, t(3;10)(p22;q26)
46, XX, t(3;10)(p24;q26)
46, XX, t(7;9)
46, XX, t(1;19)(q32;q13.3)
46, XX, t(2;8)(q31;q22)
46, XX, t(1;19)(q1.2;q13.1)
46, XX, t(5;19)(p13;p12)
46, XX, t(2;10)(p22;p14)
46, XX, t(2;8)
46, XX, t(2;12)

3.3 Controlled Ovarian Stimulation

We measured total gonadotrophin administered to each patient in every cycle and the results were: 4201.39 ± 1332.14 IU for EQc, and 2532.05 ± 742.33 IU for the pathological group, with significant difference $p \leq 0.000$. This confirms that the stimulation response is not affected by a higher dose of gonadotrophin administration in the translocated group, given the same results were obtained even with lower gonadotrophin dose administration. We analyze the COS response, and for the analysis of the number of oocytes in mature oocytes (MII) we take the number of oocytes as covariant ($F 1.300 = 1173.808$; $p \leq 0.000$), the latter being a significant variable. The effect of the group on the number of oocytes in MII was not significant ($F 1.300 = 2.250$; $p = 0.135$). The mean was greater in the group of patients with translocation (11.28 MII; TD = 4 51) compared to those who did not have translocation (9.68 MII; TD = 6 13) (Table 6).

Control group had a mean number of MII oocytes (8.85 MII;TD = 5.73), while in translocation group was (11.00 MII; TD= 4.8) ($F1.38 = 12,164$; $p = 0.01$), being greater in women with translocation. When a comparison is made for both groups neutralizing the effect of the oocytes with the inter-subject effects test (not taking into account the number of oocytes extracted but only those that were in MII) we saw that there was a significant statistical difference.

Regarding the maturation rate of the oocytes, control group had (87.54%; TD = 19.12) in contrast, in women with translocation it was (92.39%; TD = 13.34) ($F_{1,38} = 1.594$; $p = 0.214$) ($t_{360} = -0.521$; $p = 0.602$).

When performing the intra-subject effects test for both groups, we found that there was no significant difference between the groups studied.

When comparing the study group with the “equivalent control” (EQc), the three factors measured were compared one by one to reveal no significant differences (Table 6).

Table 6. Mature oocytes recovery, maturation rate and divided embryos comparing pathologic vs EQc group

P vs EQc	N Oocytes	N MII	% MII	% Fertilization	N Embryos
Control EQc (N=22)	9.00±5.49	7.86±5.82	82.58±22.71	81.93±25.19	5.68±3.68
Pathologic (N=19)	11.11±5.59	10.05±5.77	88.37±16.96	80.74±25.16	7.89±4.54
<i>p</i>	0.23	0.24	0.38	0.89	0.09

The number of zygotes with 2 pronuclei did not show significant differences ($t_{362} 1.046$; $p = 0.296$) between the two groups. In the study group, it was (6.34 zygotes; TD = 3.64) versus the control group (5.82 zygotes; TD = 4.42) and was higher in patients with translocations. Comparing our results in all stimulation cycles in both groups of patients we confirmed previous results, no differences were observed in number of oocytes, division rate, fertilization rate or number of embryos obtained (Table 6; Figs. 3 and 4).




Fig. 3. Comparison of N. of oocytes, N. of MII and N. of embryos between pathologic group and QEc group




Fig. 4. Results of maturation rate and fertilization rate between pathologic group and EQc group

4. DISCUSSION

It is known that the incidence of chromosomal translocations in general population is around 0.2% [24], but this rate is increased at the infertile individuals, so that in our studied group of infertile females is 0.5%, according to expected. Patients with chromosomal translocations has been reported to have a higher risk of reproductive failure, including recurrent spontaneous miscarriage or implantation failure, and the pattern of segregation at meiosis plays an important role on genetical inheritance of the embryos generated [25]. Additionally, it is relevant to consider the known inter-chromosomal effect (ICE) that leads, especially in Robertsonian translocations, to a generalised increase in the risk of producing aneuploidy in gametes [18]. When embryo chromosomal screenings are applied, abnormalities are revealed not only affecting the specific chromosomes involved in the translocation, but also are detected aneuploidies affecting other chromosomes as a result of the ICE effect [26]. This is a major concern to take under consideration when counselling patients about the risk of abnormal conception or probability of producing healthy embryos suitable for uterine transfer during cycles of IVF with PGT. Another worry we have for a successful PGT treatment is to know if balanced chromosomal translocated female patients are candidates to have a diminished ovarian reserve and if will manifest a poor response in an ovarian controlled stimulation, because the better the response to drug is, the better the prognosis will be.

There have been several works, mainly case reports, relating a diminished follicular production or excessive apoptosis related with long arm of X chromosome implicated in a chromosomal aberration. One study reports gonadal dysgenesis in two patient's carriers of a balanced translocation [27], with no phenotype abnormality or malformation other than ovarian failure, but the authors do not mention whether it was a coincidental event or a consequence of the balanced translocation. Further, a case report of a young woman 18 years old with amenorrhea had associated a balanced autosomal translocation between chromosomes 1 and 11 and a clinical suggestive of hyper gonadotrophic hypogonadism [28]. Another case report shows a diminished ovarian reserve in a woman with a balanced translocation of chromosomes 13 and 21, but with a familiar history of early menopause, and no other case reported in the literature with this aberration associated to diminished ovarian reserve [29]. But most gonadal dysgenesis has been reported in association with chromosomal translocation between the X chromosome and an autosome 4, 6, 9, 12, 15 and 18 [30,31,32,33].

It was our concern to find out if balanced translocation patients may have a normal response to gonadotrophin stimulation or if there is a diminished ovarian response, compared to a control group with normal karyotype, to guide the process for couples to undergo an IVF treatment with PGT. The literature published on this subject is not conclusive; on one side there is the Chen et al. work [13]

concluding that female carriers of a balanced chromosomal translocation are at risk for a poor response to ovarian stimulation. On the other side, the work conducted by Dechanet et al. [34] sustains that those groups of patients had a normal pattern of response to ovarian stimulation and conclude that translocation did not influence the ovarian response in an IVF-PGT procedure. Both studies chose as a control group patients in whom the translocation carrier was the male partner. But we decided to compare our group of female carriers with a control group of infertile patients without chromosomal aberrations in any of the partners to compare the ovarian response to stimulation, and we found no differences between groups. Also, because our control group was significantly younger and with lower BMI, and knowing that ovarian reserve is related to woman's age, we made the additional comparison with an equivalent control group with no differences in age, BMI or FSH, matching a control with a pathological patient one by one, to conclude that no differences are encountered in stimulation results: number of oocytes, maturation rate, fertilization rate and embryo number. Our results are more coincident with Dechanet et al. conclusions. The purpose to achieve a large embryos number available for biopsy must be determinant to select the normal ones for transfer. Therefore, it is of utmost importance to have a good ovarian response to gonadotrophin stimulation. Most case reports associate chromosome translocation with ovarian dysfunction implying X chromosome, and in our patient series there are not any case involving X chromosome, so the results obtained can be not accurate for those patients. But the results obtained in our study group conclude that there is no decrease in the ovarian response in chromosomal translocated patients, which confirms no different ovarian reserve, as well as no difference in the maturation rate, fertilization rate or number of embryos obtained.

Nevertheless, female translocated carriers are known to have a less stringent checkpoint of germline cells, compared to males, to repair and activate the apoptosis proceeding to eliminate abnormal oocytes from unbalanced meiotic segregation [35]. This is the reason for females to have a higher proportion of 3:1 segregation pattern and a diminished proportion of alternate segregation than males [12].

On the other side, when the carrier of the translocation is the male, the prevalence of chromosomal alterations is greater in infertile males, in fact, the probability of finding an altered karyotype is inversely proportional to the spermatoc count. The carriers of a chromosomal translocation have an increased risk of having a reproductive failure or affecting the offspring due to producing unbalanced gametes.

In the general population, it is known according to the bibliography already published [8,36] that the percentage of reciprocal translocation is around 0.2% while the Robertsonian translocations is around 0.12%. It is known that this percentage is increased in infertile couples (0.6%) compared to the general population [37]. And it is greater this frequency in individuals with implantation failures (1.4%), and especially in individuals of couples with repeated abortions (4.1%) [38]. Studies of large series like that of Gekas J. et al. [39] get among a population of infertile patients a frequency of 1.23 % of males with RT and 0.82% with ROT. According to these publications, in our study we have found that monitoring a population of infertile patients, the index of translocations we have found is 1.9% in male carriers of chromosomal translocation, 1.13% RT and 0.82% of ROT, so we can say that our population of infertile males is adjusted to the expected frequencies of translocation carriers.

Since we know the existence of the apoptosis phenomenon, selective process that excludes the proportion of germinal cells unbalanced during spermatogenesis and that alters the spermatoc parameters of these infertile men, we know that those patients who present translocations, theoretically must have a higher incidence of oligozoospermia and azoospermia due to this phenomenon [40,36], [41]. Following this principle, we check in the present study that effectively the population of males with a translocation have a sperm count significantly lower than the control group, highlighting the diagnosis of azoospermia with more prevalence even that of oligozoospermia. In addition, when we study the frequency of a sperm pathology due to genetic alteration, we observe that there is a higher incidence of males with azoospermia and severe oligozoospermia (according to guide 22 of SEF(Spanish Society of Fertility)) [42], which leads us to be able to affirm that in the cases in which couples are treated where male presents some of these sperm pathologies, it is indicated to

carry out the study of the karyotype as an initial test of the couple study to discard possible structural alterations such as reciprocal and Robertsonian translocations .

The condition of aneuploid / euploid of the gametes obtained after meiosis depends on the types of meiotic segregation (alternating, adjacent I, adjacent II, 3: 0, 3: 1 and 4: 0) predominant in each patient translocation carrier and the influence of the intercomosomal effect phenomenon (ICE). In studies like the one developed by Benet et al. [16], indicate a percentage of aneuploid gametes in male patients carriers of reciprocal translocation ranging between 18.6% and 80.7% while the percentage of Robertsonian translocations ranges between 3.4 % and 40% [14]. Since *a priori* in patients carriers of a translocations we do not know what kind of segregation is being dominant, it is recommended in those cases to perform a FISH in spermatozoa to determine what would be the probability of obtaining healthy embryos and later being able to provide a genetic advice to the couple [43].

Analyzing the results of our semen determinations we can state that the detection of a chromosomal rearrangement in the karyotype of a patient has a negative correlation on the sperm concentration [44,45], since patients carrying some translocation have a decrease in sperm concentration in fresh compared to control subjects, also observed by other authors [40]. Fresh concentration has greater rigor diagnosis that the concentration in MSR because it allows a seminal diagnosis of pathology, while concentration of MSR is variable depending on the volume of media used on resuspension and the training technique used, and that is the reason why in our study we have centered on the seminal parameters in fresh. In published studies of male chromosomal aberrations like the one performed by Van Assche et al., correlate these with a decline in sperm motility, fact that is not confirmed in our study in fresh samples, but observed significantly after sperm capacitation, what indicates that it would be interesting to expand the number of patients studied with this pathology to confirm this observation. When a male has a low sperm concentration or an increased anomalous morphology and present a normal karyotype, it is known to have an increased risk to have aneuploidies in the sperm, especially in sexual chromosomes. However this fact is not confirmed when he presents a decrease in motility [46]. Therefore, the results obtained in the present study regarding sperm motility does not determine when setting guidelines of clinical performance according to the Andrology Manual of the Spanish Society of Fertility [Brascesco et al., 2011]; [47], The study of male sterility should systematically include the karyotype and the study of aneuploidies in the spermatozoa using the technique of FISH, therefore, it is recommended that for patients with low motility or sperm concentration to perform a diagnostic test to make an estimate of the percentage of affected sperm and determine the probability of having a chromosomal alteration in the offspring and therefore in these cases recommend a preimplantation genetic test, PGT.

5. CONCLUSION

When a woman is carrier of a chromosomal translocation, has a normal ovarian response to a COS with no diminished obtention of oocytes and embryos than women with a normal XX karyotype.

And when in the study of the sterile couple the male is diagnosed with a pathologic finding with a reduced sperm concentration, asthenozoospermia, severe oligozoospermia or cryptozoospermia, a karyotype must first be performed to rule out possible chromosomal alterations. The realization of a FISH in spermatozoa is also indicated to those male patients who present severe oligozoospermia, in couples with idiopathic sterility, in implantation failures and males of couples with repeating abortions, since these could be carriers of a translocations.

In addition, patients with a balanced chromosomal translocation must be counselled to have IVF treatment with PGT to improve pregnancy rate and diminish the incidence of recurrent miscarriage, particularly to patients with a previous history of recurrent pregnancy loss, being informed the female carriers of no different COS pattern than normal karyotyped females.

Furthermore, in future, the issues of genetic counseling should be treated with an increasingly particular attention focused on fertility care, within the framework of the open coordination method with other health professionals in the field of human reproduction.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Ogilvie CM, Scriven PN. Meiotic outcomes in reciprocal translocation carriers ascertained in 3-day human embryos. *Eur J Hum Genet.* 2002; 10(12):801–6.
2. Scott JM, Eccles J, Iturriaga A, Zimmerman RS. Translocations, inversions and other chromosome arrangements. *Fertil Steril.* 2017;107(1):19-26.
3. Gardner RJM, Sutherland GR. *Chromosome Abnormalities and Genetic Counselling.* Oxford University Press. 2003;604.
4. Benito Jiménez C FJEN. *Genética: Conceptos esenciales.* In: Médica Panamericana, editor. *Genética: Conceptos esenciales.* 10 Edición. 2013;594.
5. Tucker JD. Low-dose ionizing radiation and chromosome translocations: A review of the major considerations for human biological dosimetry. *Mutat Res - Rev Mutat Res.* 2008;659(3):211–20.
6. Kim S R, Shaffer L G. Robertsonian Translocations: Mechanisms of Formation, Aneuploidy, and Uniparental Disomy and Diagnostic Considerations. *Genetic Testing. Original Contributions.* 2002;6(3).
7. Shaffer LG, Jackson-Cook CK, Stasiowski BA, Spence JE, Brown JA. Parental origin determination in thirty de novo Robertsonian translocations. *Am J Med Genet.* 1992;43(6):957–63.
8. Fryns JP, Van Buggenhout G. Structural chromosome rearrangements in couples with recurrent fetal wastage. *Eur J Obstet Gynecol Reprod Biol.* 1998;81(2):171–6.
9. Therman E, Susman B, Denniston C. The non-random participation human acrocentric chromosomes in Robertsonian translocations. *Ann Hum Genet.* 1989;53:49–65.
10. Cummings MR, William S. Klug CAS. *Mutaciones cromosómicas: variación en el número y ordenación de los cromosomas.* In: Pearson, editor. *Conceptos de Genética.* 8ª Edición. Madrid. 2006;213–43.
11. Zhang L, Wei D, Zhu Y, Jiang W, Xia M, Li J, Yan J, Chen ZJ. Interaction of acrocentric chromosome involved in translocation and sex of the carrier influences the proportion of alternate segregation in autosomal reciprocal translocations. *Hum Reprod* 2019;34:380-387. DOI: 10.1093/humrep/dey367
12. Lin L, Chen X, Wang J, Li R, Ding Ch, Cai B, Zhou C, Xu Y. Effect of carriers sex on meiotic segregation patterns and chromosome stability of reciprocal translocations. *RBMO*; 2021. DOI: org/10.1016/j.rbmo.2021.08.017
13. Chen SH, Escudero T, Cekleniak NA, Sable DB, Garrisi MG, Munne S. Patterns of ovarian response to gonadotropin stimulation in female carriers of balanced translocation. *Fertil Steril.* 2005;83(5):1504-9.
14. Roux C, Tripogney C, Morel F, Joanne C, Fellmann F, ClavequinMC, et al. Segregation of chromosomes in sperm of Robertsonian translocation carriers. *Cytogenet Genome Res.* 2005;296:291–6.
15. Chang EM, Han JE, Kwak IP, Lee WS, Yoon TK, Shim SH. Preimplantation genetic diagnosis for couples with a Robertsonian translocation: Practical information for genetic counselling. *J Assist Reprod Genet.* 2012;29(1):67–75.
16. Benet J, Oliver-Bonet M, Cifuentes P, Templado C, Navarro J. Segregation of chromosomes in sperm of reciprocal translocation carriers:A review. *Cytogenet Genome Res.* 2005;111(3–4):281–90.
17. Singhal P, Pendkur G, Parihar RS, Singh S, Chakrabarty BK and Raghavendra SK. The spectrum of chromosomal abnormalities and endocrine profile of male infertility with nonobstructive semen abnormality: A case-control study. *J Hum Reprod Sci.* 2021;14(2):175-183. DOI: 10.4103/jhrs_165_20
18. Alfawati S, Fragouli E, Colls P, Wells D. Embryos of Robertsonian translocation carriers exhibit a mitotic interchromosomal effect that enhances genetic instability during early development. *PLOS Genet.* 2012;8(10):1-10.

19. Otani T, Roche M, Mizuike M, Colls P, Escudero T and Munné S. Preimplantation genetic diagnosis significantly improves the pregnancy outcome of translocation carriers with a history of recurrent miscarriage and unsuccessful pregnancies. *RBM Online*. 2006;13(6):869-874.
20. Munné S, Chen S, Fischer J, Colls P, Zheng X, Stevens J, et al. Preimplantation genetic diagnosis reduces pregnancy loss in women aged 35 years and older with a history of recurrent miscarriages. *Fertil Steril*. 2005;84:331-5.
21. World Health Organization. WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple [Internet]. Available:<https://books.google.es/books?id=9HUcx4ViQ9kC&printsec=frontcover&hl>
22. Rooney DE, Czepulkowski BH, (eds). *Human Cytogenetics, a practical approach*, Vol. 1. IRL Press at Oxford University Press. 1992;36-41.
23. ASEBIR. Cuadernos de Embriología Clínica. Criterios ASEBIR de Valoración Morfológica de Oocitos, Embriones Tempranos y Blastocistos Humanos. 3ª Edición; 2015.
24. Jacobs PA, Melville M, Ratcliffe S, Keay AJ, Syme J. A cytogenetic survey of 11,680 newborn infants. *Ann Hum Genet*. 1974;37:359-76.
25. Jacobs PA, Pertile M, Norris H and Baker HWG. Chromosome translocations in couples with *in-vitro* fertilization implantation failure. *Hum Reprod*. 1999;14(8):2097-2101.
26. Fiorentino F, Spizzichino L, Bono S, Biricik A, Kokkali G, Rienzi L, et al. PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. *Hum Reprod*. 2011;26;1925-1935.
27. Tupler R, Barbierato L, Larizza D, Sampaolo P, Piovella F, Maraschio P. Balanced autosomal translocations and ovarian dysgenesis. *Hum Genet*. 1994;94(2):171-176.
28. Tullu MS, Arora P, Parmar RC, Muranjan MN, Bharucha BA. Ovarian dysgenesis with balanced autosomal translocation. *J Postgrad Med*. 2001;47:113. [Cited 2018 Oct 18]. Available:<http://www.jpgmonline.com/text.asp?2001/47/2/113/216>
29. Kummer N, Martin R, Pal L. Diminished ovarian reserve in a woman with a balanced 13;21 translocation. *Fertil Steril*. 2009;91(3):931.e3-931.e5.
30. Center JR, McElduff A, Roberts CG. Premature ovarian failure and ovarian dysgenesis associated with balanced and unbalanced X-6 translocations, respectively: Implications for the investigation of ovarian failure. *Aust N Z J Obstet Gynaecol*. 1994;34:185-8.
31. Larizza D, Maraschio P, Maghnie M, Sampaolo P. Hypogonadism in a patient with balanced X/18 translocation and pituitary hormone deficiency. *Eur J Pediatr*. 1993;152:424-7.
32. Ji XW, Chen XY, Tan J, Liang H. Balanced X;15 translocations 46, X, t(X;15) (q21; q23) associated with primary amenorrhea. *Am J Med Genet*. 1988;31:783-786.
33. Fusco F, Paciolla M, Chen E, Li X, Genesio R, Conti A, et al. Genetic and molecular analysis of a new unbalanced X;18 rearrangements: localization of the diminished ovarian reserve disease locus in the distal Xq POF1 region. *Hum Reprod*. 2011;26(11):3186-96. DOI: 10.1093/humrep/der266. Epub 2011 Aug 22.
34. Dechanet C, Castelli C, Reyftmann L, Hamamah S, Hedon B, Dechaud H, Anahory T. Do female translocations influence the ovarian response pattern to controlled ovarian stimulation in preimplantation genetic diagnosis? *Hum Reprod*. 2011;26(5):1232-1240.
35. Jaramillo-Lambert A, Harigaya Y, Vitt J, Villeneuve A, Engebrencht J. Meiotic errors activate checkpoints that improve gamete quality without triggering apoptosis in male germ cells. *Curr Biol*. 2010; 20:2078-2089. DOI:10.1016/j.cub.2010.10.008
36. Antonio M, Loera Z, Mart R. Causas genéticas de la infertilidad. *IECH*. 2013;1-8.
37. Hook EB, Hamerton J. The frequency of chromosome abnormalities detected in consecutive newborn studies Differences between studies. Results by sex and by severity of phenotypic involvement. In: Academic Press N York, editor. In Hook, E. 1977;66-79.
38. Stern C, Pertile M, Norris H, Hale L, Baker HWG. Chromosome translocations in couples with *in-vitro* fertilization implantation failure. *Hum Reprod*. 1999;14(8):2097-101.
39. Gekas J, Thepot F, Turleau C, Siffroi JP, Dadoune JP, Briault S, et al. Chromosomal factors of infertility in candidate couples for ICSI: An equal risk of constitutional aberrations in women and men. *Hum Reprod*. 2001;16(1):82-90.
40. Brugnol F, Janny L, Communal Y, Darcha C, Szczepaniak C, Pellestor F, et al. Apoptosis and meiotic segregation in ejaculated sperm from Robertsonian translocation carrier patients. *Hum*

- Reprod. 2010;25(7):1631–42.
41. Van Assche E, Bonduelle M, Tournaye H, Joris H, Verheyen G, Devroey P, et al. Cytogenetics of infertile men. *Hum Reprod* [Internet]. 1996;11(suppl 4):1–26.
Available: https://academic.oup.com/humrep/articlelookup/doi/10.1093/humrep/11.suppl_4.1.
 42. Brassesco M. Manual de andrología. Soc Española de Fertil [Internet]. 2011;1–55.
Available: <http://www.sefertilidad.net/docs/grupos/andro/manual.pdf>
 43. Godo A, Vidal F, Blanco J. Desequilibrios cromosómicos en espermatozoides de individuos portadores de translocaciones recíprocas. *Rev Embriol Clínica y Biol la Reprod*. 2012;17:12–6.
 44. Abramsson L, Beckman G, Duchek M, Nordenson I. Chromosomal aberrations and male infertility. *J Urol* [Internet]. 1982;128(1):52–3.
Available: [http://dx.doi.org/10.1016/S0022-5347\(17\)52752-4](http://dx.doi.org/10.1016/S0022-5347(17)52752-4)
 45. Clementini E, Palka C, Iezzi I, Stuppia L, Guanciali-Franchi P, Tiboni GM. Prevalence of chromosomal abnormalities in 2078 infertile couples referred for assisted reproductive techniques. *Hum Reprod*. 2005;20(2):437–42.
 46. Qinghua Shi and Renée H. Martin. Aneuploidy in human spermatozoa: FISH analysis in men with constitutional chromosomal abnormalities, and in infertile men. *Reproduction*. 2001;121:655–666.
 47. Committee E. Guide to the quality and safety of tissues and cells for human application. Assisted reproductive technology. In: 3rd ed. France. 2017;261–80.

Biography of author(s)



Salma Kaddouri-Kaddouri

Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.

She was born in Casablanca, Morocco, in 1991 and she was raised in South Spain, Almeria. She studied Biology, in the University of Murcia and She has completed a master's degree in Human Reproduction, in the University of La Laguna, Tenerife, Spain. She worked for two years at the Pathology department, at the University Hospital, Landspítali. In January 2021, she started training and working as an Embryologist at Livio clinic, Iceland. To this day, she has published two articles in collaboration with the Human Reproduction department (Tenerife): 1. "Males carrying a chromosomal translocation present more pathological spermograms than normal males XY". *Revista Iberoamericana de Fertilidad y Reproducción Humana* / Vol. 35 nº 4 Octubre-Noviembre-Diciembre 2018; 2. "Does female with chromosome translocation have a normal response to controlled ovarian hyperstimulation?" *International Research Journal of Medicine and Medical Sciences* Vol. 8(4), pp. 109-115, October 2020.



Cintia Concepción-Lorenzo

Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

She Works as an embryologist since 2006, first for private clinics, after for public hospital in Tenerife and continues an ongoing process in the lab job. She studied Bachelors degree (1999 to 2004) in Biology at La Laguna University, Tenerife, Spain, and Master(2005 to 2006) in Human Reproduction at Madrid, Spain. She has been a member of the ASEBIR Association since 2007. In 2011, she was certified as Clinical Embryologist by ESHRE, and in 2018 she was certified as Senior Embryologist by ESHRE. She has Guidance role as Practice and Study Assistant for academic year 2017-2018 in post-graduate qualification "Master Universitario en Reproducción Humana" at La Laguna University, Tenerife. She has Presentation of works or posters in National and International Congress: ASEBIR Congress: 2007, 2017 and 2021, SEF Congress: 2010 and 2018, ESHRE Congress: 2012, ASRM Congress: 2009 and 2013. She is a Co-author in scientific publications: "Males carrying a chromosomal translocation present more pathological spermograms than normal males XY". *Revista Iberoamericana de Fertilidad y Reproducción Humana* / Vol. 35 nº 4 Octubre-Noviembre-Diciembre 2018; and "Does female with chromosome translocation have a normal response to controlled ovarian hyperstimulation?" *International Research Journal of Medicine and Medical Sciences* Vol. 8(4), pp. 109-115, October 2020.



Rubí N. Rodríguez-Díaz

Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.

Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

She is a Specialist in Obstetrics and Gynecology, and she has dedicated her work life to Human Reproduction and university teaching. She has master's degree in administration and direction of Health services by the University of Valencia, specialist in reproduction and Assisted Psychological aspects, doctors and legal by the University of Online Education. In 1985, she began as an assistant professor of practical classes of obstetrics and Gynecology at the University of La Laguna where she obtained the Professor position in 1991. With several book chapters and books published, as well as diverse papers in impact journals, her research lines have been those related to vaginitis and sexually transmitted diseases, embryonic cryopreservation and the relationship of heavy metals in semen and follicular liquid with the reproduction. Some of the most relevant publications are: 1.-Pregnancy with Frozen-Thawed and Fresh Testicular Biopsy After Motile and Immotile Sperm; 2.-Microinjection, using the mechanical touch technique to assess viability, Human Reproduction. 3. -Human Zygote Morphological Indicators of Higher Rate of Arrest at The First -Cleavage Stage. Zygote. 4.-Genital infection and sterility, Infectious diseases and clinical microbiology; 5.-Gestation rate and β HCG levels in transfer of frozen and fresh embryos, Cuban magazine of obstetrics and gynecology; 6.-Embryo sHLA-G Secretion Is Related to Pregnancy Rate. Zygote; 7.-Associations of Semen Quality with Seminal Non-Essential Heavy Metals in Male from The Canary Islands, Biological Trace Element Research.

Stephany Hess-Medler

Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.

She is an Associate professor in the area of Methodology of Behavioural Sciences at the University of La Laguna, where she took her doctorate. Her research centres on methods, environmental psychology, neuropsychology and assisted reproduction. She is a member of the Environmental Psychology and Neuropsychology research teams and has participated in numerous funded research projects for these topics. She is a founding member of the editorial board of the Psychology journal and a reviewer for several scientific journals with JCR impact factor. She is a member of the Spanish and the European Association of Methodology as well as a member of the Association of Environmental Psychology. She published numerous articles in international JCR impact factor journals and has presented scientific papers at numerous national and international conferences. She teaches methods on the Bachelor's in Psychology, the University Masters' degrees in HR Development and Management, and in General Health Psychology, as well as on the Master for assisted reproduction. ORCID: 0000-0002-0289-8796, ResearcherID: O-3016-2013, ScopusID: 56185135700, LoopID: 438821.



Jonay González-Pérez

Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

He is an Embryologist in University Hospital of Canary Islands. He obtained a degree in Biology from the University of La Laguna in 2003 and Master's degree in Assisted Human Reproduction at the Complutense University of Madrid in 2004. He has 16 years of experience in the IVF laboratory as an Embryologist in the University Hospital of Canary Islands. He has been professor of the Master of Assisted Human Reproduction at the University of La Laguna. He has participated in national and international Congresses with great interest in the evaluation of male reproductive pathology. He has participated in several scientific papers: -Human zygote morphological indicators of higher rate of arrest at the first cleavage stage. Zygote.19 (4), 339-44. 2011;2. -International Research Journal of Medicine and Medical Sciences. Vol.8(4), pp.109-115. Oct. 2020. DOI: 10.30918/IRJMMS.84.20.043; 3. "Males carrying a chromosomal translocation present more pathological spermograms than normal males XY". Revista Iberoamericana de Fertilidad y Reproducción Humana/Vol. 35 nº 4 Octubre-Noviembre-Diciembre 2018; 4."Does female with chromosome translocation have a normal response to controlled ovarian hyperstimulation?" International Research Journal of Medicine and Medical Sciences Vol. 8(4), pp. 109-115, October 2020 DOI: 10.30918/IRJMMS.84.20.043.



Delia R. Báez-Quintana

Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.

Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

She is a Professor of Gynecology and Obstetrics, Equality Representative at the Faculty of Medicine of the University of La Laguna, Teacher in gender master from the same University, Founding member of Cesex (center for human sexuality studies), Director and Teaching Coordinator of master's degree Own title of Human Reproduction, and Head of Section of the Human Reproduction Unit of the Canary Islands Health Service. Some of her Recent publication : 1. Altered expression of the tachykinins substance P/neurokinin A/hemokinin-1 and their preferred neurokinin 1/neurokinin 2 receptors in uterine leiomyomata Fertility and Sterility. 106:1521-1529.-(6), 2016. pp.1521-1529; 2. Differentially regulated expression of neurokinin B(NKB)/NK3 receptor system in uterine leiomyomata HUMAN REPRODUCTION. OXFORD UNIV PRESS, GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND. 28-7, 2013.pp.1799-1808. WOS (9) ; 3. NEUROTENSIN AND NEUROTENSIN RECEPTOR 1 EXPRESSION IN HUMAN MYOMETRIUM AND UTERINE LEIOMYOMAS BIOLOGY OF REPRODUCTION. SOC STUDY REPRODUCTION. 83-4, 2010. pp.641-647 ; 4. CHARACTERIZATION OF ESTROGEN RECEPTORS ALPHA AND BETA IN UTERINE LEIOMYOMA CELLS FERTILITY AND STERILITY. ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA. 86-6, 2006. pp.1736-1743; 5. Comparative Analysis of the ER alpha/ER beta Ratio and Neurotensin and its High-affinity Receptor in Myometrium, Uterine Leiomyoma, Atypical Leiomyoma, and Leiomyosarcoma INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY. 19106-3621 USA. 30-4, 2011.pp.354-363. 6. 2011. ESTRÓGENOS Y PÉPTIDO NEUROTENSINA EN NEOPLASIAS DE MIOMETRIO Biocancer. 5. 7. RELEVANCIA CLINICA E HISTOPATOLOGICA DE LAS DELECCIONES DEL CROMOSOMA Y EN LA POBLACIÓN CANARIA Revista Internacional de Andrología. Elsevier. 4-3, pp.94-96. 8 Dual agonist-antagonist effect of ulipristal acetate in human endometrium and myometrium Expert Review of Molecular Diagnostics, DOI:10.1080/14737159.2021.1941878. Taylor and Francis. Pp.1-7. Proyects : 1 CELLULAR AND MOLECULAR BASES OF THE ACTION OF SEXUAL STEROIDS IN THE FORMATION OF UTERINE TUMORS (ICIC -P.I. 02/2004. CANARIAN INSTITUTE FOR CANCER RESEARCH. (FACULTY OF BIOLOGIES). 2004-2006; 2 ESTRADIOL AND FSH RECEPTORS IN FEMALE GENITAL TISSUES. (HOSPITAL UNIVERSITARIO DE CANARIAS). 1989-1990; 3 Contract. Cellular and molecular effect of PGL4001 on the uterus of women treated for fibroids by means of a prospective, double-blind, randomized, parallel-group, placebo-controlled study. Gedeon Ritche Laboratories. Since 2015.



Raquel Blanes-Zamora

Universidad de La Laguna (ULL), Santa Cruz de Tenerife, Canary Islands, Spain.
Unidad de Reproducción Humana (URH). Complejo Hospital Universitario de Canarias (CHUC), La Laguna, Santa, Cruz de Tenerife, Canary Islands, Spain.

She obtained PhD degree in Medical Science, Department of foetal-maternal health, BS degree in Biological Sciences, and Master Degree in Human Microbiota. She is a Professor in Master's degree of Human Reproduction, Collaborating in the teaching of various subjects in medicine degree as Professor *Venia Docendi* at University of La Laguna., and a Human Embryologist at the Hospital Universitario de Canarias (CHUC). She acted as referee in several scientific papers. She has multiple scientific publications and communications to congresses. The most relevant: 1. The oxidizing agent butyl hydroperoxide induces disturbances in spindle organization, c-meiosis, and aneuploidy in Mouse oocytes. Molecular Human Reproduction, vol.2 n° 12, 895-901. 1996; 2. Pregnancy with frozen-thawed and fresh testicular biopsy alter motile and immotile sperm microinjection, using the mechanical touch technique to assess viability. Human Reproduction, Vol.19 (2), 262-265. 2004; 3. Human zygote morphological indicators of higher rate of arrest at the first cleavage stage. Zygote. 19 (4), 339-44. 2011; 3. Microbiome and Fertility. Annals of Clinical Obstetrics and Gynecology. Vol 1 pp.1-4. April 2019; 4. Embryo sHLA-G secretion is related to pregnancy rate" Zygote. <https://www.cambridge.org/core>. 2019; 5. International Research Journal of Medicine and Medical Sciences. Vol.8(4), pp.109-115. Oct. 2020. DOI: 10.30918/IRJMMS.84.20.043; 6. Microbiome and Fertility. Review Article. Annals of Clinical Obstetrics and Gynecology. Vol 1 pp.1-4. April 2019; 7. Association of semen quality with seminal non-essential heavy metals in males from the Canary Islands. Biological Trace Element Research. 10 Feb.2021. doi.org/10.1007/s12011-021-02605-5; 8. Chapter 2. Sperm DNA Fragmentation. Assisted Reproductive Technology www.avidscience.com. September 11, 2017.

© Copyright (2021): Author(s). The licensee is the publisher (B P International).

DISCLAIMER

This chapter is an extended version of the article published by the same author(s) in the following journal. International Research Journal of Medicine and Medical Sciences, 8(4): 109-115, 2020.